Lithium Drilling Program Commences at East Vallée
TORONTO, June 03, 2024 (GLOBE NEWSWIRE) — Consolidated Lithium Metals Inc. (TSXV: CLM | OTCQB: JORFF | FRA: Z36) (“CLM” […]
Osisko Development to Complete Second Deferred Payment Installment in Connection With the Tintic Acquisition
MONTREAL, June 03, 2024 (GLOBE NEWSWIRE) — Osisko Development Corp. (NYSE: ODV, TSXV: ODV) (“Osisko Development” or the “Company“) announces […]
Whitestone REIT Continues Board Refreshment
Announces Board Leadership Changes Intends to Add Two New Trustees HOUSTON, June 03, 2024 (GLOBE NEWSWIRE) — Whitestone REIT (NYSE: […]
iBio Closes Sale of Manufacturing Facility in Texas
– The sale of the facility eliminates $13.2M of secured debt – – Completes iBio’s transition to an AI and precision biologics […]
Century Therapeutics Presents Interim Results from Phase 1 ELiPSE-1 Study at ASCO 2024 Annual Meeting
In ongoing dose escalation, CNTY-101 has demonstrated a manageable safety profile with no observed DLTs or GvHD and with majority […]
Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at American Society of Clinical Oncology (ASCO) Annual Meeting
HOUSTON, June 03, 2024 (GLOBE NEWSWIRE) — Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery […]
Entrada Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference
BOSTON, June 03, 2024 (GLOBE NEWSWIRE) — Entrada Therapeutics, Inc. (Nasdaq: TRDA) is a clinical-stage biopharmaceutical company aiming to transform […]
Alpine Income Property Trust Announces Sale of a Senior Portion of First Mortgage Loan Investment
WINTER PARK, Fla., June 03, 2024 (GLOBE NEWSWIRE) — Alpine Income Property Trust, Inc. (NYSE: PINE) (the “Company” or “PINE”) […]
Worthington Enterprises Completes Acquisition of Hexagon Ragasco
COLUMBUS, Ohio, June 03, 2024 (GLOBE NEWSWIRE) — Worthington Enterprises (NYSE: WOR), a designer and manufacturer of market-leading brands that […]
IN8bio Presents Progression-Free Survival Update from Phase 1 Study of INB-200 at 2024 American Society of Clinical Oncology Annual Meeting
92% of evaluable patients treated with INB-200 for glioblastoma exceeded a median progression-free survival (PFS) of seven months achieved with […]
